Web of Biological Data Act of 2026
Introduced June 11, 2026 · Last action June 11, 2026
Plain English Summary
This bill requires the Department of Energy to set up a centralized database and resource center that makes biological research data openly accessible to scientists and researchers, with tools to use artificial intelligence and advanced computational methods to analyze that data. The goal is to accelerate biological research by removing barriers to accessing datasets that are currently scattered across different institutions and agencies.
Who benefits
Academic researchers and university biology departments; pharmaceutical and biotechnology companies developing new drugs and therapies; artificial intelligence and machine learning software companies; federal research institutions (NIH, NSF-funded labs); startup biotech firms seeking access to large datasets; hospitals and medical research centers conducting clinical studies; foreign and domestic research teams using U.S. biological datasets.
Who pays / loses
U.S. taxpayers fund the Department of Energy's development and maintenance of this centralized database system; companies and institutions currently profiting from proprietary control over biological datasets may lose competitive advantage if data becomes more widely available; federal agencies currently managing siloed biological datasets may incur integration and coordination costs.
Funding & Lobbying Interests
Biotechnology and pharmaceutical industry groups (e.g., Biotechnology Industry Organization, Pharmaceutical Research and Manufacturers of America) typically lobby for expanded data access and AI-enabled research infrastructure. Academic research institutions and university associations support centralized data platforms. AI and software companies (including cloud computing providers) benefit from expanded datasets and computational research workloads. The Department of Energy's national laboratories and ARPA-E have existing interests in biological data infrastructure. Sponsors of such legislation typically receive contributions from technology sector donors, research institution leadership, and life sciences industry PACs.
Political Impact
Affected Groups
Biological and medical researchers (estimated 200,000+ active life science researchers in U.S. universities and private labs); pharmaceutical and biotech companies (approximately 5,000+ firms in U.S. biotech sector); artificial intelligence researchers and machine learning engineers using biological datasets; undergraduate and graduate students in biology, medicine, and computational biology; international research collaborators with U.S. institutional affiliations; patients who may benefit from faster drug discovery and medical breakthroughs enabled by AI-accelerated research.
Political Subtext
Proponents frame this as necessary infrastructure for American competitiveness in AI-driven biology research, arguing centralized access accelerates medical breakthroughs and keeps cutting-edge research in the U.S. rather than moving to countries with more open data policies. They emphasize benefits for public health and economic growth. Critics might argue the bill lacks oversight mechanisms for data privacy and security, could create cybersecurity vulnerabilities by centralizing sensitive biological data, or may insufficiently protect intellectual property interests of companies that contributed data. The non-partisan case for centralized research infrastructure is well-established (NIH and NSF have made similar arguments for open science), though implementation details on data governance, security protocols, and cost-sharing are critical and not specified in this bill text.
Real-World Stakes
If enacted, the U.S. would join other advanced economies (EU, China, Canada) in creating national biological data commons accessible to AI researchers. Success depends on whether the resource achieves high-quality, well-organized, secure data that attracts researchers—similar to how NIH's Gene Expression Omnibus and the Cancer Genome Atlas have accelerated research by democratizing access. Failure risks wasting resources on an unused or poorly-designed platform. The bill does not specify budgets, governance structure, data security standards, or whether participation is mandatory or voluntary, leaving implementation and real-world impact unclear. Analogous efforts like the NIH All of Us Research Program (launched 2018, $1.46 billion authorized) show both potential (millions of health records accessible) and challenges (recruitment targets missed, privacy concerns).
What's Inside This Bill
Non-obvious provisions not apparent from the headline summary.
Biosafety and Dual-Use Research Screening Exemption
The bill requires the database to make biological research data 'openly accessible' without explicitly defining screening mechanisms for dual-use research of concern (DURC) or pathogenic agent information that could pose biosecurity risks.
AffectsBiosecurity officials and public health agencies may lack authority to restrict access to sensitive pathogen sequences or gain-of-function research data, potentially affecting oversight of research with pandemic potential. Foreign nationals and non-credentialed researchers could access information typically restricted under biosafety protocols.
AI Training Data Restrictions Absence
The bill mandates making biological data 'openly accessible' with 'tools to use artificial intelligence' but does not restrict how third parties can use the centralized database for training large language models or commercial AI applications.
AffectsResearchers whose data is included lose control over commercial AI model training using their work. Private companies could use taxpayer-funded biological datasets to develop proprietary AI systems without attribution or benefit-sharing.
No Intellectual Property or Patent Protection Carve-Out
The centralized database requirement does not exclude or protect patent-pending research, trade secrets, or pre-publication data that institutions may have submitted under different agreements.
AffectsUniversities and research institutions with pending patents or licensing agreements may face disputes over data ownership. Small biotech companies could have proprietary research inadvertently exposed through institutional data contributions.
Undefined 'Openly Accessible' Standards
The bill requires data be made 'openly accessible' but does not specify data governance standards, who maintains access controls, retention periods, or whether researchers can later request data removal.
AffectsResearchers have no clear mechanism to protect privacy-sensitive research or withdraw data. Institutions cannot enforce data use agreements or track unauthorized secondary uses of their research.
Sponsor
Co-sponsors (2)
RRep. Baird, James R. [R-IN-4]DRep. Auchincloss, Jake [D-MA-4]
Vote Record
No recorded votes.
Campaign Finance — Primary Sponsor
No campaign finance data available yet.
501(c)(4) disclosure: Contributions from 501(c)(4) "dark money" organizations are not required to be publicly disclosed and are not reflected in the figures above. Data sourced from FEC public disclosure filings.
Community Discussion
Share this bill
Sign in to join the discussion.
No comments yet. Be the first.